Alcohol Use Disorder
5
Pipeline Programs
5
Companies
7
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
1
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
AlkermesDUBLIN 4, Ireland
2 programs1
1
XR-NTX 380 mg, intramuscular injectionPhase 41 trial
XR-NTXPhase 21 trial
Active Trials
Heidelberg PharmaGermany - Ladenburg
2 programs1
Oxytocin nasal sprayPhase 2/31 trial
PIT paradigmN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
AlkermesXR-NTX 380 mg, intramuscular injection
Heidelberg PharmaOxytocin nasal spray
MediciNovaIbudilast
AlkermesXR-NTX
Novo NordiskDCR-AUD
BrainsWayDeep TMS
Heidelberg PharmaPIT paradigm
Clinical Trials (7)
Total enrollment: 280 patients across 7 trials
Naltrexone in AUD Reward Drinkers
Start: Mar 2022Est. completion: Jul 2028
Phase 4Recruiting
Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder
Start: Dec 2021Est. completion: Sep 202362 patients
Phase 2/3Completed
Ibudilast for the Treatment of Alcohol Use Disorder
Start: Oct 2018Est. completion: Apr 2023102 patients
Phase 2Completed
Harm Reduction With Pharmacotherapy (HaRP)
Start: Aug 2013Est. completion: Jun 2019
Phase 2Completed
Phase 1b Study of DCR-AUD in Healthy Volunteers
Start: Jan 2023Est. completion: Aug 202316 patients
Phase 1Completed
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)
Start: Nov 2025Est. completion: Dec 2027
N/ARecruiting
Effect of Social Isolation on the Role of Pavlovian Mechanisms for Control Over Alcohol Use
Start: Oct 2024Est. completion: Jun 2027100 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 280 patients
5 companies competing in this space